Evidence map›Paper›PMID 41580502›Full record

ArticleScientific reports2026

Patient profiles, incidence and trends of lung cancer in Ethiopia from 2012 to 2023 using a cancer registry.

Nathan Estifanos, Gudina Egata, Adamu Addissie, Tewodros H Gebremariam, Rahel Argaw Kebede, Hanan Yusuf, Mathewos Assefa, Solomon Asmare, Ahmedin Jemal, Negussie Deyessa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nathan EstifanosSchool of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. estifanos9090@gmail.com.ORCID http://orcid.org/0000-0001-5598-2206
Gudina EgataSchool of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Adamu AddissieSchool of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Tewodros H GebremariamDivision of Pulmonary Sciences & Critical Care, Department of Medicine, Denver Health Medical Center, Denver, CO, USA.
Rahel Argaw KebedeCollege of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Hanan YusufCollege of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Mathewos AssefaOncology Department, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Solomon AsmareAddis Ababa Cancer Registry, Addis-Ababa-University, Addis Ababa, Ethiopia.
Ahmedin JemalDepartment of Surveillance and Health Services Research, American Cancer Society, Atlanta, GA, USA.
Negussie DeyessaSchool of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Funding

Addis Ababa University Award Number 6417Bristol Myers Squibb Foundation 61329475
6 · The paper itself

Abstract

Lung cancer epidemiology varies widely across countries, yet local data remain scarce. This study analyzed 882 lung cancer cases registered in the Addis Ababa population-based cancer registry from 2012 to 2023 to characterize patient profiles, incidence rates, and trends. We used descriptive statistics, binary and multinomial logistic regression, Poisson regression, and joinpoint regression. We found the crude median age at diagnosis was 56 years (adjusted: 60 years), with one in four patients diagnosed before 45. Adenocarcinoma was the most common histological subtype (34.8%), significantly associated with females (AOR: 1.64, 95% CI: 1.21–2.21), followed by squamous cell carcinoma (8.8%). Carcinoma not otherwise specified (NOS) accounted for 45.2% of cases. Alarmingly, 93% of patients were diagnosed at a late stage. The age-standardized incidence rate (ASIR) was 3.1 per 100,000 (3.3 for males, 2.8 for females), with a male-to-female incidence rate ratio (IRR) of 1.13, showing a nonsignificant decline over time. The incidence rate increased with age and varied significantly across sub-cities (1.5–2.9 per 100,000). While the overall ASIR trend remained stable, sex-specific trends showed a 3% annual increase in female crude incidence rates, whereas male rates remained unchanged significantly. These findings highlight the urgent need for targeted lung cancer prevention, early detection, and treatment strategies tailored to local epidemiological patterns.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsAdultAgedAged, 80 and overEthiopiaFemaleHumansIncidenceMaleMiddle AgedRegistriesYoung AdultCancerEthiopiaIncidenceLung cancerPatient profilesTrends

Identifiers

PMID41580502
PMCPMC12905398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.